iShares US Pharmaceuticals ETF
94 hedge funds and large institutions have $133M invested in iShares US Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 43 reducing their positions, and 15 closing their positions.
283% more call options, than puts
Call options by funds: $4.53M | Put options by funds: $1.18M
0.45% more ownership
Funds ownership: 35.59% → 36.05% (+0.45%)
4% less capital invested
Capital invested by funds: $139M → $133M (-$5.64M)
7% less funds holding
Funds holding: 101 → 94 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
77% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 43
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Karp Capital Management
Sausalito,
California
|
+$2.62M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.47M |
| 3 |
Morgan Stanley
New York
|
+$2.01M |
| 4 |
MGIA
Matthew Goff Investment Advisor
Houston,
Texas
|
+$860K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.22M |
| 2 |
AWA
ARS Wealth Advisors
St. Petersburg,
Florida
|
-$3.09M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.79M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$989K |
IHE Hedge Fund Activity: Q2 2018 in Review
94 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2018, worth a combined $133M — down 4.1% from $139M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IHE and 8 opened new positions — a net loss of 7 holders — while 43 trimmed existing stakes and 10 added.
The largest buyer was Karp Capital Management, adding an estimated $2.62M. The largest seller was Bank of America, cutting an estimated $4.22M.
- 94 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2018, down from 101 in Q1 2018.
- Funds reported $133M of iShares US Pharmaceuticals ETF stock for Q2 2018, down 4.1% quarter-over-quarter.
- 8 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2018 and 15 closed out, a net change of -7 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2018 was Karp Capital Management, an estimated $2.62M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2018 was Bank of America, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2018.